Celon Pharma SA CLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.48
- Dividend Yield (Trailing)
- 0.60%
- Dividend Yield (Forward)
- 0.60%
- Total Yield
- 0.60%
Company Profile
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 513
- Website
- http://www.celonpharma.com
Comparables
Valuation
|
Metric
|
CLN
|
TLX
|
AMLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 112.59 | 1.68 |
Price/Book Value | 1.65 | 31.09 | 0.31 |
Price/Sales | 4.48 | 9.19 | 0.36 |
Price/Cash Flow | 28.34 | 191.10 | 1.79 |
Price/Earnings
CLN
TLX
AMLX
Financial Strength
|
Metric
|
CLN
|
TLX
|
AMLX
|
|---|---|---|---|
Quick Ratio | 1.44 | 1.19 | 5.01 |
Current Ratio | 1.74 | 1.43 | 5.66 |
Interest Coverage | −6.13 | 1.15 | — |
Quick Ratio
CLN
TLX
AMLX
Profitability
|
Metric
|
CLN
|
TLX
|
AMLX
|
|---|---|---|---|
Return on Assets (Normalized) | −4.48% | 3.71% | 18.55% |
Return on Equity (Normalized) | −5.76% | 11.73% | 21.48% |
Return on Invested Capital (Normalized) | −5.23% | 18.08% | 17.45% |
Return on Assets
CLN
TLX
AMLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Kzlqzdfd | Xbwlh | $71.2 Bil | |
ZTS
| Zoetis Inc Class A | Cjgpxjdp | Yqsg | $68.3 Bil | |
HLN
| Haleon PLC ADR | Ndzpfwgk | Gjh | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Fjzysbh | Qbht | $14.5 Bil | |
VTRS
| Viatris Inc | Qhtxcfnwj | Djjm | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Brygshrg | Hycr | $11.9 Bil | |
CTLT
| Catalent Inc | Wbkpgfnht | Fjzcjkr | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Kxrxmlpp | Cswnw | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Grssnwhy | Mmsl | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jqkwzjmy | Mqflfnm | $3.5 Bil |